WallStSmart
PVLA

Palvella Therapeutics, Inc

NASDAQ: PVLA · HEALTHCARE · BIOTECHNOLOGY

$130.17
+0.54% today

Updated 2026-05-06

Market cap
$1.82B
P/E ratio
P/S ratio
EPS (TTM)
$-3.70
Dividend yield
52W range
$20 – $151
Volume
0.3M

Palvella Therapeutics, Inc (PVLA) Financial statements

SEC filings — annual and quarterly data.

Income statement — annual

Item2013201420152016201720182019202020212022202320242025
Revenue$12.43M$5.37M$2.93M$5.83M$25.27M$29.10M$46.28M$29.32M$31.42M$25.90M$0.00$0.00$0.00
Revenue growth (YoY)-56.8%-45.3%+98.9%+333.5%+15.1%+59.0%-36.6%+7.1%-17.6%-100.0%
Cost of revenue$2.37M$2.78M
Gross profit$29.32M$29.05M$23.12M
Gross margin0.0%0.0%0.0%0.0%0.0%0.0%0.0%100.0%92.5%89.3%
R&D$9.41M$5.60M$7.64M$19.70M$21.92M$40.92M$54.36M$44.22M$64.20M$50.21M$8.79M$8.15M$22.84M
SG&A$4.16M$3.08M$5.94M$15.76M
Operating income$553826.00$-7.20M$-13.08M$-22.76M$-14.59M$-30.83M$-27.16M$-33.92M$-51.83M$-43.47M$-11.87M$-14.10M$-38.60M
Operating margin4.5%-134.2%-446.1%-390.3%-57.7%-105.9%-58.7%-115.7%-165.0%-167.8%
EBITDA$944813.00$-6.83M$-13.55M$-22.28M$-16.18M$-26.50M$-24.43M$-34.94M$-43.37M$-30.50M$18.69M$-13.12M$-35.90M
EBITDA margin7.6%-127.3%-462.0%-382.0%-64.0%-91.0%-52.8%-119.2%-138.0%-117.7%
EBIT$560136.00$-7.19M$-13.85M$-22.64M$-16.54M$-27.07M$-25.47M$-37.07M$-45.74M$-33.28M$-11.87M$-14.10M
Interest expense$493937.00$2.65M$0.00$4.32M$5.82M
Income tax
Effective tax rate0.0%0.0%0.0%0.0%0.0%0.0%0.0%0.0%0.0%0.0%0.0%0.0%0.0%
Net income$66196.00$-9.85M$-14.06M$-22.80M$-17.65M$-26.75M$-25.47M$-37.23M$-45.74M$-33.28M$18.69M$-17.43M$-41.72M
Net income growth (YoY)-14980.1%-42.7%-62.2%+22.6%-51.6%+4.8%-46.2%-22.9%+27.2%+156.2%-193.3%-139.3%
Profit margin0.5%-183.6%-479.5%-391.0%-69.8%-91.9%-55.0%-127.0%-145.6%-128.5%